



Cell Source Appoints Dr. Robert Negrin to Its Scientific Advisory Board

NEW YORK, NY -- (Marketwired) -- 07/06/15 -- Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Robert S. Negrin, Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University, has joined its Scientific Advisory Board.

Itamar Shimrat, CEO of Cell Source stated "We are delighted to have Dr. Negrin join our Scientific Advisory Board. He has a very deep understanding of the use of immunotherapy for both stem cell transplantation and cancer treatment. He also has a very practical approach to cell production and administration of cell therapy treatments. Having taught at Stanford for 25 years, Dr. Negrin has spent the past decade focusing on the use of T cells in immunotherapy, precisely the area in which Cell Source is developing its Veto Cell technology. Dr. Negrin will surely help us to optimize our clinical trials as well as our development of commercial production capacity."

Dr. Negrin stated, "I very much look forward to bringing these important ideas into the clinic." Dr. Negrin received his medical degree at Harvard Medical School and training in Internal Medicine and Hematology at Stanford University. He is the Program Leader of the Immunology and Immunotherapy of Cancer Program at the Stanford University Cancer Center. He is currently an Associate Editor of Blood (the weekly journal of the American Society of Hematology) and has served on the editorial boards of the Journal of Clinical Oncology and Biology of Blood and Marrow Transplantation.

Dr. Negrin has served as the President of the American Society of Bone and Marrow Transplantation and the International Society of Cellular Therapy. He is an elected member of the Association of American Physicians. Dr. Negrin has earned research awards from the National Institutes of Health, the Leukemia Society of America and the Jose Carreras Leukemia Foundation and was a Doris Duke Distinguished Clinical Scientist Awardee.

About Cell Source, Inc.

Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine.

For more information go to www.cell-source.com

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate, as well as the risk factors disclosed in Cell Source, Inc.'s Form 10-K filed on March 13, 2015. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

INVESTOR, MEDIA & GENERAL CORPORATE CONTACT:

Cell Source, Inc.

Phone: +1 (646) 612-7554

Toll Free: +1 (888)-315-4650

Email: info@cell-source.com

Source: Cell Source, Inc.